Needham Maintains a Buy Rating on Dermira (DERM)


In a report released today, Serge Belanger from Needham maintained a Buy rating on Dermira (DERM), with a price target of $22.00. The company’s shares closed last Monday at $5.69, close to its 52-week low of $5.25.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -3.5% and a 40.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Collegium Pharmaceutical, and Flexion Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dermira with a $22.00 average price target.

See today’s analyst top recommended stocks >>

Based on Dermira’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.96 million. In comparison, last year the company had a GAAP net loss of $66.54 million.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts